Oncoinvent AS, a clinical stage radiopharmaceutical company advancing alpha emitter therapy across a variety of peritoneal metastases, announced that the US Food and Drug Administration (FDA) has granted Fast Track designation to Radspherin for the treatment of patients with peritoneal metastases from ovarian cancer.
Oncoinvent Receives FDA Fast Track Designation for Radspherin® as Treatment for Peritoneal Carcinomatosis from Ovarian Cancer
Oncoinvent to Present at Cantor Fitzgerald Frontiers in Radiopharma Virtual Summit
Oncoinvent Announces Changes to its Board of Directors and Formation of Scientific and Clinical Advisory Board
Oncoinvent to Present at Evercore ISI 2024 Emerging Biotech Conference
Oncoinvent Announces U.S. FDA Clearance of IND Application for Radspherin
Oncoinvent Announces U.S. FDA Clearance of Investigational New Drug (IND) Application for Radspherin® in Colorectal Cancer Patients
Oncoinvent Presents Preliminary 18-Month Safety and Efficacy Data from Ongoing RAD-18-002 Phase 1/2A Trial of Radspherin® in Colorectal Cancer Patients at the 13th PSOGI International Congress on Peritoneal Surface Malignancies
Oncoinvent To Present Initial Safety Data from the Phase 1 Trial of Radspherin® in Ovarian Cancer Patients at the 24th Congress of the European Society of Gynaecological Oncology (ESGO)
OSLO, Norway--(BUSINESS WIRE)--Oncoinvent AS, a clinical stage company advancing alpha emitter therapy to treat cancers, today announced the appointment of Anders Månsson as Chief Executive Officer (CEO), effective September 1st, 2023.